From friend to foe: proviral role of IRF-3 in chronic gammaherpesvirus infection
Project Number5R21AI182596-02
Contact PI/Project LeaderTARAKANOVA, VERA L.
Awardee OrganizationMEDICAL COLLEGE OF WISCONSIN
Description
Abstract Text
Abstract
Gammaherpesviruses establish life-long infections in >95% of adults worldwide and are
associated with B cell lymphomas. Gammaherpesvirus-driven cancers develop in both
immunocompromised and immunocompetent individuals; prevention of such cancers is
currently impossible due to absence of vaccines, curative antivirals, and defined risk factors for
lymphomagenesis. Manipulation of B cell differentiation lies at the heart of chronic
gammaherpesvirus infection and pathogenesis. Specifically, gammaherpesviruses use natural
proliferative capacity of germinal center B cells to amplify latent viral reservoir. Further,
germinal center B cells are believed to be the target of viral transformation, as a majority of
gammaherpesvirus-driven B cell lymphomas are germinal center-derived. Despite the
importance of germinal center response for chronic infection and lymphomagenesis, very few
factors that control infection of germinal center B cells have been defined. Interferon Regulatory
Factor 3 (IRF-3) is a transcription factor that targets many cellular genes, including interferon
(IFN) β. We discovered that, contrary to the predicted role of IRF-3 as an antiviral factor, IRF-3
supports latent gammaherpesvirus infection of germinal center B cells. The proposed studies
test the hypothesis that IRF-3 is usurped by gammaherpesvirus to facilitate latent infection of
germinal center B cells, with subsequent generation of memory B cells that host life-long latent
viral reservoir. This is achieved through IRF-3-dependent regulation of cellular and viral target
genes. Successful completion of the proposed studies will offer an insight into the mechanism
by which the virus usurps a classical innate antiviral factor for the viral benefit.
Public Health Relevance Statement
Narrative:
Over 95% of adults are infected with gammaherpesviruses that are known to drive development of B cell
lymphomas. Unfortunately, very little is known about the viral and host factors that influence the development
of gammaherpesvirus-driven lymphomas. This proposal will determine how a classical antiviral factor of the
host is usurped by gammaherpesviruses to establish life-long infection.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
937639060
UEI
E8VWJXMMUQ67
Project Start Date
19-January-2024
Project End Date
30-November-2025
Budget Start Date
01-December-2024
Budget End Date
30-November-2025
Project Funding Information for 2025
Total Funding
$191,148
Direct Costs
$130,277
Indirect Costs
$60,871
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$191,148
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21AI182596-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21AI182596-02
Patents
No Patents information available for 5R21AI182596-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21AI182596-02
Clinical Studies
No Clinical Studies information available for 5R21AI182596-02
News and More
Related News Releases
No news release information available for 5R21AI182596-02
History
No Historical information available for 5R21AI182596-02
Similar Projects
No Similar Projects information available for 5R21AI182596-02